A Study Evaluating Soticlestat in Participants With Dravet Syndrome or Lennox-Gastaut Syndrome Who Have Been Exposed to Fenfluramine
An Open-label, Nonrandomized, Phase 3 Study to Evaluate the Efficacy and Safety of Soticlestat in Participants With Dravet Syndrome or Lennox-Gastaut Syndrome Who Have Been Exposed to Fenfluramine
Sponsor: Takeda
Terminated
Business decision unrelated to patient safety.
Other terminated trials from Takeda
Other Dravet Syndrome (DS) trials with similar outcome
A PHASE3 clinical study on Dravet Syndrome (DS) and Lennox-Gastaut Syndrome (LGS), this trial is terminated or withdrawn. The trial is conducted by Takeda and has accumulated 6 data snapshots since 2024. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
6 versions recorded-
Aug 2025 — Present [monthly]
Terminated PHASE3
-
Apr 2025 — Aug 2025 [monthly]
Terminated PHASE3
-
Oct 2024 — Apr 2025 [monthly]
Terminated PHASE3
Status: Recruiting → Terminated
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE3
▶ Show 1 earlier version
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE3
First recorded
Apr 2024
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Takeda
For direct contact, visit the study record on ClinicalTrials.gov .